Vapocoolant Spray to Reduce Pain With Nexplanon Insertion
The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures.
| Condition(s) | Reducing Pain With Nexplanon Implant Insertion |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The purpose of this study is to assess if Pain Ease vapocoolant spray decreases pain associated with lidocaine injection during Nexplanon insertion procedures. |
| Who can participate | Inclusion Criteria: * At least 14 years or older * Undergoing an etonogestrel implant insertion in the arm in POB1 Suite 1004 or POB2 Suite 402 * English speaking * Able and willing to sign the informed consent form and agree to terms of the study Exclusion Criteria: * Required or requested narcotics, anxiolytics, IV sedation, or general anesthesia for the procedure * Known previous exposure to vapocoolant spray * Nexplanon removal and reinsertion same day during visit in the same arm * Contraindications to vapocoolant spray components (ethyl chloride and 1,1,1,3,3-pentafluoropropane/1,1,1,2-tetrafluroethane) * Unable to provide written, informed consent in English |
| Ages | 14 Years |
| Sex | Female |
| Accepts healthy volunteers | Yes |
| Lead sponsor | Queen's Medical Center |
| Locations | Honolulu, Hawaii, United States; Honolulu, Hawaii, United States; Waimea, Hawaii, United States |
| Start date | 2025-06-16 |
| NCT ID | NCT06933381 |
| Official listing | https://clinicaltrials.gov/study/NCT06933381 |